Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.82), $1.08 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $44.91 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst
• GE Vernova (GEV) PT Raised to $1,185 at Jefferies